---
title: "Xtandi (enzalutamide) in castration-resistant prostate cancer: Guidelines questions"
description: "Guidelines questions on Xtandi (enzalutamide) in castration-resistant prostate cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Do NCCN and AUA guidelines recommend Xtandi (enzalutamide)? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xtandi (enzalutamide) in castration-resistant prostate cancer: Guidelines questions

Manufacturer: Astellas Pharma US, Inc.; Pfizer Inc.  
Prescribing information: [Xtandi](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf)

Questions that apply to every indication of Xtandi are on [Xtandi (enzalutamide), all indications](https://www.evicenter.com/medical-information/xtandi).

## Guidelines

<a id="xtandi-guidelines"></a>

### Do NCCN and AUA guidelines recommend Xtandi (enzalutamide)?

> “Enzalutamide (XTANDI®) is recommended in the NCCN Guidelines® and American Urological Association (AUA)/Society of Urologic Oncology (SUO) Advanced Prostate Cancer Guideline.<sup>4,5</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Treatment for nmCRPC & mCRPC, captured 2026-11-13](https://www.xtandihcp.com/crpc/home#:~:text=Enzalutamide%20%28XTANDI%C2%AE%29%20is%20recommended%20in,Oncology%20%28SUO%29%20Advanced%20Prostate%20Cancer)

> “Enzalutamide (XTANDI) + ADT is an NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Category 1 treatment option across all 4 disease states<sup>1</sup>”

Source: [XTANDI: XTANDI® Treatment Guidelines, captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/guidelines#:~:text=Enzalutamide%20%28XTANDI%29%20%2B%20ADT%20is,option%20across%20all%204%20disease)

> “Please see the NCCN Guidelines® at nccn.org for full recommendations, including other preferred options.”

Source: [XTANDI: XTANDI® Treatment Guidelines, captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/guidelines#:~:text=Please%20see%20the%20NCCN%20Guidelines%C2%AE,recommendations%2C%20including%20other%20preferred%20options.)

> “*A Category 1 recommendation is based upon high-level evidence (≥ 1 randomized phase 3 trials or high-quality, robust meta-analyses) and indicates there is uniform NCCN consensus (≥ 85% support of the Panel) that the intervention is appropriate.<sup>1</sup>”

Source: [XTANDI: XTANDI® Treatment Guidelines, captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/guidelines#:~:text=%2AA%20Category%201%20recommendation%20is,Panel%29%20that%20the%20intervention%20is)

> “<sup>‡</sup>A Category 2A recommendation is based upon lower-level evidence and indicates there is uniform NCCN consensus (≥ 85% support of the Panel) that the intervention is appropriate.<sup>1</sup>”

Source: [XTANDI: XTANDI® Treatment Guidelines, captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/guidelines#:~:text=Category%202A%20recommendation%20is%20based,Panel%29%20that%20the%20intervention%20is)

> “<sup>§</sup>For patients with adenocarcinoma mCRPC regardless of prior docetaxel therapy and no prior novel hormone therapy.<sup>1</sup>”

Source: [XTANDI: XTANDI® Treatment Guidelines, captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/guidelines#:~:text=patients%20with%20adenocarcinoma%20mCRPC%20regardless,and%20no%20prior%20novel%20hormone)

> “American Urological Association (AUA)/Society of Urologic Oncology (SUO) Advanced Prostate Cancer Guideline recommends enzalutamide (XTANDI)<sup>2-4</sup>”

Source: [XTANDI: XTANDI® Treatment Guidelines, captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/guidelines#:~:text=American%20Urological%20Association%20%28AUA%29%2FSociety%20of,Prostate%20Cancer%20Guideline%20recommends%20enzalutamide)

> “1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer V.1.2027. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed October 13, 2026.”

Source: [XTANDI: XTANDI® Treatment Guidelines, captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/guidelines#:~:text=1.%20Referenced%20with%20permission%20from,reserved.%20Accessed%20October%2013%2C%202026.)

> “3. Scarpato KR, Cookson MS, Dreicer R, et al. Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Published May 26, 2026. Accessed May 26, 2026.”

Source: [XTANDI: XTANDI® Treatment Guidelines, captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/guidelines#:~:text=3.%20Scarpato%20KR%2C%20Cookson%20MS%2C,2026.%20Accessed%20May%2026%2C%202026.)

Note: The guidelines page presents the recommendation for each disease state in a graphic whose text was not captured. The footnotes quoted here qualify entries of that graphic; the capture does not show which entry each footnote marks. The page was captured November 13, 2026.

## Related pages
- [Medical information: Xtandi (enzalutamide): Castration-resistant prostate cancer](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer)
- [Indication](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/dosing-and-administration)
